
Pharmacally
Solid Tumors
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Solid Tumors
Mergers & AcquisitionsJazz and AbCellera Partner to Develop T-Cell Engagers for GI and Solid Tumors in Deal Worth Up to $792 Million per ProgramJazz Pharmaceuticals and AbCellera have formed a strategic research and licensing collaboration to advance multispecific T-cell engagers for gastrointestinal cancers and other solid tumors.Fact-Checked
Clinical TrialsReplimune’s RP2 Shows Durable Responses in Advanced Solid TumorsReplimune Group unveiled final Phase 1 results for RP2, its next-generation HSV‑1–based oncolytic immunotherapy, during an oral session at ASCO 2026.Fact-Checked
Clinical TrialsBoehringer Ingelheim Unveils New Zongertinib and Obrixtamig Results Across Solid TumorsAt ASCO 2026, Boehringer Ingelheim unveiled new patient-reported outcomes and expanded efficacy data for HERNEXEOS® (zongertinib) in HER2-driven solid tumors, alongside updated Phase I results for obrixtamig in…Fact-Checked
Clinical TrialsGigaGen Reports Early Phase 1 Data for GIGA-564 in Advanced Solid Tumors at AACR 2026Early clinical data presented by GigaGen Inc. at American Association for Cancer Research 2026 highlight promising safety and preliminary efficacy of GIGA-564 in patients with advanced solid tumors.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.